Inflammasomes in rheumatoid arthritis: a pilot study

Area of Science:

• Immunology
• Molecular Biology
• Rheumatology

Background:

• The inflammasome is implicated in rheumatoid arthritis (RA) pathogenesis, but systematic reporting is limited.
• Understanding inflammasome levels in relation to RA severity could inform treatment strategies.

Purpose of the Study:

• To investigate the relationship between inflammasome levels and RA disease severity.
• To identify potential molecular targets for RA treatment.

Main Methods:

• Quantitative real-time PCR (qRT-PCR) measured mRNA levels of inflammasomes (NLRP3, NLRC4, AIM2, caspase-1, IL-1beta, NLRP1, NLRP2, NLRC5) in PBMCs from RA patients and healthy controls (HC).
• Enzyme-linked immunosorbent assay (ELISA) quantified plasma IL-1beta and IL-18 levels.
• Clinical data and laboratory results of RA patients were analyzed.

Main Results:

• RA patients exhibited significantly higher mRNA expression of NLRP3, NLRC4, AIM2, caspase-1, and IL-1beta compared to HC.
• RA patients showed significantly lower mRNA expression of NLRP1, NLRP2, and NLRC5 compared to HC.
• Plasma IL-1beta and IL-18 levels were markedly increased in RA patients.
• AIM2 mRNA levels negatively correlated with Disease Activity Score 28 (DAS28).
• Erythrocyte sedimentation rate (ESR) positively correlated with DAS28.

Conclusions:

• The findings highlight the critical roles of NLRP3, NLRC4, AIM2, caspase-1, and plasma IL-1beta and IL-18 in RA pathogenesis.
• These inflammasomes represent potential therapeutic targets for RA treatment.